hyodeoxycholic acid | 30634-98-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: hyodeoxycholic acid
• 英文别名: alpha-Hyodeoxycholic acid；(4R)-4-[(3R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• CAS: 30634-98-1
• 化学式: C₂₄H₄₀O₄
• 分子量: 392.579
• InChiKey: DGABKXLVXPYZII-CDONHWFASA-N

物化性质

• 熔点：
  205 °C
• 沸点：
  547.1±25.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 溶解度：
  0.0598 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20150119345A1

  公开（公告）日：2015-04-30

  Provided herein are methods for treating or preventing gastrointestinal and/or liver infections utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists. Also provided herein are methods for increasing the levels of an enteroendocrine peptide or hormone in an individual suffering from a gastrointestinal infection or liver infection utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists.

  本文提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂治疗或预防胃肠和/或肝感染的方法。本文还提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂增加患有胃肠感染或肝感染的个体体内肠内分泌肽或激素水平的方法。
• Beta-cyclodextrin dimers and phthalocyanines and uses thereof
  申请人：——

  公开号：US20030134824A1

  公开（公告）日：2003-07-17

  The invention provides &bgr;-cyclodextrin dimers and phthalocyanines which can be used in photodynamic therapy of cancer.

  这项发明提供了可用于癌症光动力疗法的β-环糊精二聚体和酞菁化合物。
• Lipid probes and uses thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10168342B2

  公开（公告）日：2019-01-01

  Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

  披露了用于识别脂质结合蛋白作为药物结合靶点的方法、组合物、探针、检测和试剂盒。此外，还披露了用于绘制脂质结合蛋白上的配体结合位点、识别脂质结合蛋白、生成药物-脂质结合蛋白轮廓、高通量药物筛选以及识别作为潜在脂质结合蛋白配体的药物的方法、组合物和探针。
• LONG-ACTING RASAGILINE PRODRUG, PREPARATION METHOD AND USE THEREOF
  申请人：Guangzhou Henovcom Bioscience Co., Ltd

  公开号：EP3674289A1

  公开（公告）日：2020-07-01

  Provided are a long-acting prodrug of Rasagiline, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected from (II); each of R1 and R2 is independently selected from H, D, and alkyl; W is absent, or W is selected from (CH2)n, wherein n is an integer selected from 1 to 15; X is absent, or X is selected from (CH2)m, wherein m is an integer selected from 1 to 10; Y is absent, or Y is selected from -C(=O)NH-, -NHC(=O)-; R3 is selected from substituted or unsubstituted C1-C30 alkyl, substituted or unsubstituted C2-C30 alkenyl, substituted or unsubstituted C2-C30 alkynyl, substituted or unsubstituted C3-C30 cycloalkyl, cholane aliphatic group, -R3a-C(=O)O-R3b, -R3a-OC(=O)-R3b, -R3a-C(=O)NH-R3b, -R3a-NHC(=O)-R3b, -R3a-S(=O)1-2O-R3b and -R3a-OS(=O)1-2-R3b. The provided prodrug of Rasagiline has a high melting point and low solubility, and it can form a drug reservoir in the body after being administered if it is made in a form of injection, prolonging the release rate of the prodrug in the body and achieving an effect of long-acting treatment.

  提供了拉沙吉林的长效前药、制备方法及其用途。拉沙吉林的长效前药具有如下结构式（I），其中T为空缺，或T选自（II）；R1和R2中的每一个独立选自H、D和烷基；W为空缺，或W选自（CH2）n，其中n为1至15之间的整数；X为空缺，或X选自（CH2）m，其中m为1至10之间的整数；Y为空缺，或Y选自-C(=O)NH-、-NHC(=O)-；R3选自取代或未取代的C1-C30烷基、取代或未取代的C2-C30烯基、取代或未取代的C2-C30炔基、取代或未取代的C3-C30环烷基、胆烷脂肪基、-R3a-C(=O)O-R3b、-R3a-OC(=O)-R3b、-R3a-C(=O)NH-R3b、-R3a-NHC(=O)-R3b、-R3a-S(=O)1-2O-R3b和-R3a-OS(=O)1-2-R3b。所提供的拉沙吉林前药具有高熔点和低溶解度，如果以注射剂形式制备，则可在体内形成药物储库，延长前药在体内的释放速率，达到长效治疗的效果。
• Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20130108573A1

  公开（公告）日：2013-05-02

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了一种治疗或改善高胆固醇血症或胆汁淤积性肝病的方法，即通过向需要的个体施用治疗有效量的顶端钠依赖性胆酸转运蛋白抑制剂（ASBTI）或其药用可接受盐。还提供了一种治疗或改善肝病、降低血清胆酸或肝内胆酸水平、治疗或改善瘙痒、降低肝酶或减少胆红素的方法，即通过向需要的个体施用治疗有效量的ASBTI或其药用可接受盐。